Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02689830
Other study ID # SA-112043
Secondary ID
Status Active, not recruiting
Phase N/A
First received February 10, 2016
Last updated July 18, 2017
Start date March 2016
Est. completion date December 2017

Study information

Verified date July 2017
Source ClinSearch
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the feasibility and safety of Prostate Artery Embolization (PAE) in patients suffering of Acute Urinary Retention (AUR) in the context Benign Prostatic Hypertrophy (BPH).


Description:

This is an open-label prospective, multicenter (centralized procedure), single arm, sequentially enrolling study. Twenty subjects will be enrolled in the study.

Patient will be referred by the attending urologists after failure of the currently recommended approach of Trial WithOut Catheter (TWOC) and alpha-adrenergic receptor (AR) blockers.

It is expected that all AUR cases referred to the local urological clinic will be considered for inclusion in the trial. A trial log book will be completed by the referring local urologist in order to obtain preliminary data on the applicability of the trial to all AUR comers in the institution. This log book will be limited to a very simple questionnaire to ensure high rate of completion by the attending resident/fellow (Patients age, size of prostate, previous Benign Prostate Hypertrophy symptoms, renal function). It will be used in order to assess the external validity of this first phase trial and will be a help to design the potential next step trial.

When a patient will present with AUR in the corresponding urological clinic, the PI and Clinical research coordinator will be informed by a short text message, fax or e-mail in order to prepare the following process.

Patient will be informed by the urologist of the ongoing research project. In summary, this will consist in informing the patient that the first step is TWOC and in case of failure of TWOC several options are offered including PAE in the trial setting. Inclusion of the patient will considered only in case of failure of TWOC.

If the patient is willing to participate, patient will be seen in clinic by the Principal Investigator or co-investigator in order to inform him of the protocol and obtain signed informed consent.

PAE will be scheduled upon the first contact to make sure that PAE is performed in a short delay following failure of TWOC. The goal is to perform PAE in the week following recatheterization. For practical reasons this delay might be extended and will be recorded in the Case Report Form.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date December 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- AUR Patients presenting with a first episode of AUR related to BPH (no matter if previously known or not) AND

- Failure of at least one TWOC AND

- Prostate size > or = 50 ml (ultrasound measurement)

Exclusion Criteria:

- Known hypocontractile bladder

- AUR related to other causes (Acute prostatitis or documented Prostate cancer)

- Severe iodine allergy

- Known prostate cancer

- Known ongoing acute or chronic prostatitis

- On-going acute pyelonephritis or septicemia from urinary origin

- Patient refusing PAE

- Severe renal failure (creatinine Clearance < 20 ml/min (MDRD)

- Contra-indication to AR blockers (postural hypotension micturition syncope)

- Contra-indication to anticoagulants

- Patient catheterized with a suspubian catheter

- Patient <18

- Patients who are prisoners

- Patients who are mentally incapacitated

- Patients participating in an investigational study involving the peripheral vasculature

- Patients unable or unwilling to provide written informed consent

- Patients ineligible for pelvic angiography and embolization including severe atheromatous condition or any anatomical condition

Study Design


Intervention

Device:
Bead Block
Prostate embolization

Locations

Country Name City State
France Hôpital Cochin Paris
France Hôpital Européen Georges Pompidou Paris
France Hôpital Saint-Louis Paris

Sponsors (3)

Lead Sponsor Collaborator
ClinSearch Biocompatibles UK Ltd, European Georges Pompidou Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedure success percentage of patients free of Foley and/or any prostate surgery 6 months after PAE
Secondary Percentage of procedure related or contributed complications 1 week after PAE
Secondary Percentage of immediate technical success of embolization Percentage of bilateral embolization 5 minutes after the beginning of the procedure
Secondary Cumulative number of per-procedure angiographic and clinical complications according to the Society of Interventional Radiology and Dindo classifications 24 hours after PAE
Secondary Immediate technical success of embolization percentage of unilateral versus percentage of bilateral embolization 5 minutes after the beginning of the procedure
Secondary Comparison of International Prostate Symptom Score between pre-PAE and 3 months post-PAE
Secondary Comparison of International Index of Erectile Function between pre-PAE and 3 months post-PAE
Secondary Comparison of Quality of Life Questionnaire between pre-PAE and 3 months post-PAE
Secondary Comparison of International Prostate Symptom Score between pre-PAE and 6 months post-PAE
Secondary Comparison of International Index of Erectile Function between pre-PAE and 6 months post-PAE
Secondary Comparison of Quality of Life Questionnaire between pre-PAE and 6 months post-PAE
Secondary Number of re-catheterization 6 months after PAE
Secondary Time of re-catheterization 6 months after PAE
Secondary Time until TransUrethral Resection of the Prostate or open surgery 6 months
Secondary Cumulative number of days with bladder catheter between PAE and 6 months post-PAE
Secondary Number of patients free of bladder catheter between PAE and 6 months post-PAE
Secondary Number of cumulated hospitalization days between initial AUR and 6 months post-PAE
Secondary Number of cumulated hospitalization days between PAE and 6 months post-PAE
Secondary Total number of consultations consultations with interventional radiologist and/or urologist between PAE and 6 months post-PAE
Secondary Prostate volume Measured with MRI or ultrasound 6 months
Secondary Comparison of the number of Benign Prostate Hypertrophy medication before and 3 months after PAE
Secondary Comparison of the number of Benign Prostate Hypertrophy medication before and 6 months after PAE
See also
  Status Clinical Trial Phase
Completed NCT01732991 - Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound N/A
Completed NCT02074644 - Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia N/A
Completed NCT02015806 - Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices N/A
Completed NCT02943070 - Rezum I Pilot Study for Benign Prostatic Hyperplasia N/A
Completed NCT00461123 - Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Phase 2
Completed NCT02940392 - Rezum FIM Optimization Study N/A
Completed NCT04331301 - Bipolar Needlescopic Enucleation Versus Vapoenucleation of BPH N/A
Completed NCT00021814 - Medical Therapy of Prostatic Symptoms Phase 3